Citation Impact
Citing Papers
Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
2014 Standout
Transient Ablation of Regulatory T cells Improves Antitumor Immunity in Colitis-Associated Colon Cancer
2014 StandoutNobel
Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States
2016
Stem Cell–Derived Culture Models of Hepatitis E Virus Infection
2018 StandoutNobel
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics
2021 Standout
The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen
2017
Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis
2017
Pan-Genotype Hepatitis E Virus Replication in Stem Cell–Derived Hepatocellular Systems
2017 StandoutNobel
Myeloid-derived suppressor cells coming of age
2018 Standout
Reversion of disease manifestations after HCV eradication
2016
Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma
2019
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
Rapamycin Sensitive ROS Formation and Na+/H+Exchanger Activity in Dendritic Cells
2012
Nonselective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis
2014
T cell exhaustion
2011 Standout
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
2016
Burden of liver diseases in the world
2018 Standout
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics
2020 Standout
Cellular senescence in aging and age-related disease: from mechanisms to therapy
2015 Standout
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
2017
Macrophages in immunoregulation and therapeutics
2023 Standout
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Hepatocellular carcinoma
2012 Standout
Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma
2020
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Renal and Extrarenal Effects of Gum Arabic (Acacia Senegal) - What Can be Learned from Animal Experiments?
2013 Standout
Effects of extracellular matrix viscoelasticity on cellular behaviour
2020 StandoutNature
HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma
2017
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
Immunological landscape and immunotherapy of hepatocellular carcinoma
2015
Organoids as an in vitro model of human development and disease
2016
Saccharomyces cerevisiae β-glucan-induced SBD-1 expression in ovine ruminal epithelial cells is mediated through the TLR-2-MyD88-NF-κB/MAPK pathway
2019
The tumor microenvironment
2020 Standout
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
2018
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
2017
Liver Transplantation for Hepatocellular Carcinoma
2008
Portal hypertensive bleeding in cirrhosis
2016 Standout
Non-alcoholic fatty liver disease
2021 Standout
Pros and Cons: Usage of organs from donors infected with hepatitis C virus – Revision in the direct-acting antiviral era
2015
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
2016
Liver Volume as a Predictor of Functional Improvement Post-DAA Treatment
2017
Immune monitoring post liver transplant
2014
Hepatic Stellate Cells in Liver Tumor
2020
Global burden of liver disease: 2023 update
2023 Standout
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
2018 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma
2017
Negative Impact of Neutrophil-Lymphocyte Ratio on Outcome After Liver Transplantation for Hepatocellular Carcinoma
2009
Effect of HCV clearance with direct-acting antiviral agents on HCC
2016
The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
2013 Standout
Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma
2007
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
2011
Molecular and cellular insights into T cell exhaustion
2015 Standout
Clinical Significance and Functional Studies of Myeloid-Derived Suppressor Cells in Chronic Hepatitis C Patients
2013
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
2016
Hepatocellular carcinoma
2022 Standout
Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?
2011
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Primary sclerosing cholangitis – a comprehensive review
2017
Studies of hepatitis E virus genotypes
2010
A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
2020 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
Liver organoids: from basic research to therapeutic applications
2019
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
The oncologic burden of hepatitis C virus infection: A clinical perspective
2017
A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1
2019 StandoutNobel
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States
2017 Standout
Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?
2017
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
2017 Standout
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Direct‐acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local‐regional therapy or liver transplant waitlist dropout
2018
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy
2016
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD
2020
Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus–infected patients treated with direct‐acting antivirals
2017
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection
2007
Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients
2016
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
Review article: liver transplantation for hepatocellular carcinoma – a critical appraisal of the current worldwide listing criteria
2014
Works of William Gelson being referenced
Flagellin Induces β-Defensin 2 in Human Colonic Ex vivo Infection with Enterohemorrhagic Escherichia coli
2016
First case of genotype 4 human hepatitis E virus infection acquired in India
2010
Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation
2015
Switching to Sirolimus-Based Immune Suppression After Liver Transplantation Is Safe and Effective: A Single-Center Experience
2010
CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection
2010
Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation
2006
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
2016
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
2016
Histological changes in HCV antibody–positive, HCV RNA–negative subjects suggest persistent virus infection
2008
Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients
2016
PTU-001 Propanolol at modest dose does not impair survival in patients with cirrhosis and refractory ascites: Abstract PTU-001 Figure 1
2012
The Pattern of Late Mortality in Liver Transplant Recipients in the United Kingdom
2011